Literature DB >> 8706941

Etiology of and therapeutic approach to synechia uteri.

J G Schenker1.   

Abstract

The universal incidence of synechia uteri (Asherman's syndrome) is steadily increasing. The main offender in the etiology of this disorder is trauma to a pregnant uterus, especially after curettage in puerperium or after missed abortion, whereas the role of infection in traumatic intrauterine adhesions should be viewed with caution. Genital tuberculosis is one of the main etiological factors of this condition. The syndrome is expressed by infertility (43%) and menstrual disorders (62%). Pregnancy, when achieved, may be complicated by premature labor, placenta previa and placenta accreta. The diagnosis is made by hystersalpingography, and mainly by hysteroscopy. Preferred treatment is lysis of adhesions by hysteroscopy, followed by immediate insertion of an intrauterine device, combined with a course of estrogens. The success of treatment regarding term deliveries and rate of abortions depends on the severity of the adhesions. We carried out studies regarding regeneration of the endometrium, and intended to induce intrauterine adhesions as a method of treatment in cases of severe uterine bleeding and as a method of contraception.

Entities:  

Mesh:

Year:  1996        PMID: 8706941     DOI: 10.1016/0028-2243(95)02315-j

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  18 in total

1.  In vitro evidence that platelet-rich plasma stimulates cellular processes involved in endometrial regeneration.

Authors:  Lusine Aghajanova; Sahar Houshdaran; Shaina Balayan; Evelina Manvelyan; Juan C Irwin; Heather G Huddleston; Linda C Giudice
Journal:  J Assist Reprod Genet       Date:  2018-02-05       Impact factor: 3.412

2.  Platelet-rich plasma in the management of Asherman syndrome: case report.

Authors:  L Aghajanova; M I Cedars; H G Huddleston
Journal:  J Assist Reprod Genet       Date:  2018-02-17       Impact factor: 3.412

3.  Hysteroscopic adhesiolysis for patients with Asherman's syndrome: menstrual and fertility outcomes.

Authors:  Nari Yamamoto; Reiko Takeuchi; Daisuke Izuchi; Norihito Yuge; Masahide Miyazaki; Masafumi Yasunaga; Katsuko Egashira; Yousuke Ueoka; Yoshihito Inoue
Journal:  Reprod Med Biol       Date:  2013-05-05

4.  Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience.

Authors:  Lusine Aghajanova; Viji Sundaram; Chia-Ning Kao; Joseph M Letourneau; Evelyna Manvelyan; Marcelle I Cedars; Heather G Huddleston
Journal:  J Assist Reprod Genet       Date:  2021-10-06       Impact factor: 3.412

5.  Effect of stem cell application on Asherman syndrome, an experimental rat model.

Authors:  Sevtap Kilic; Beril Yuksel; F Pinarli; A Albayrak; B Boztok; T Delibasi
Journal:  J Assist Reprod Genet       Date:  2014-06-29       Impact factor: 3.412

6.  Effects of endometrial stem cell transplantation combined with estrogen in the repair of endometrial injury.

Authors:  Xinrong Wang; Hongchu Bao; Xuemei Liu; Chengde Wang; Cuifang Hao
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

7.  Clinical and demographic characteristics of women with intrauterine adhesion in abuja, Nigeria.

Authors:  Efena R Efetie; Augustine C Umezulike; Ugochukwu V Okafor
Journal:  Obstet Gynecol Int       Date:  2011-12-01

8.  Intrauterine synechiae after myomectomy; laparotomy versus laparoscopy: Non-randomized interventional trial.

Authors:  Zahra Asgari; Leili Hafizi; Rayhaneh Hosseini; Atiyeh Javaheri; Hathis Rastad
Journal:  Iran J Reprod Med       Date:  2015-03

9.  The role of imaging in the investigation of Asherman's syndrome.

Authors:  I-Ferne Tan; Meiri Robertson
Journal:  Australas J Ultrasound Med       Date:  2015-12-31

10.  Role of Transforming Growth Factor-β1 and Smads Signaling Pathway in Intrauterine Adhesion.

Authors:  Umme Salma; Min Xue; Md Sayed Ali Sheikh; Xiaoming Guan; Bin Xu; Aiqian Zhang; Lihua Huang; Dabao Xu
Journal:  Mediators Inflamm       Date:  2016-02-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.